Drug Delivery in Oncology (eBook)
CXXXII, 1690 Seiten
Wiley-VCH (Verlag)
978-3-527-64776-7 (ISBN)
The authors summarize knowledge gained over the past decade, from basic concepts to successful applications in the clinic, covering active and passive targeting strategies as well as tissue-specific approaches. All current and future targeted delivery systems are discussed, from ligand-based to antibody-based polymer-based systems, right up to micro- and nanoparticulate systems. A special section covers the delivery of nucleic acid therapeutics, such as siRNA, miRNA and antisense nucleotides. In each case, a description of the basic technique is followed by a discussion of the latest preclinical and clinical developments in the field.
By virtue of its clear and didactic structure, rich illustrative material and summary chapters, this handbook and ready reference enables the efficient transfer of knowledge between different disciplines, from basic research to the clinician and vice versa. It is equally well suited for professionals, researchers and students in medical oncology and cancer biology, and is also excellent for teaching medical students the foundations of 21st century cancer chemotherapy.
Felix Kratz graduated in Chemistry from the University of Heidelberg in 1991. He then carried out postdoctoral research at the Bioinorganic Institute of the University of Florence and developed tumor-specifi c carrier systems with ruthenium(III) complexes. Since 1994 he has been Head of Macromolecular Prodrugs at the Tumor Biology Center in Freiburg, Germany, where he is now in charge of organizing and managing translational research from the laboratory to the clinic. His research areas are drug targeting, drug-delivery systems in oncology, prodrugs, receptor targeting, bioconjugate chemistry, and nanocarriers. Peter Senter earned his PhD in Chemistry from the University of Illinois in Urbana, and then carried out postdoctoral research at the Max Planck Institute in Göttingen, Germany. After various positions at the Dana Farber Cancer Institute, Bristol-Myers Squibb, and Cytokine Networks, he joined Seattle Genetics in 1998, and initiated research programs that led to the technology used for SGN-35 and other promising antibody drug conjugates. Henning Steinhagen graduated in Organic Chemistry from the University of Heidelberg, Germany in 1998. He then joined the group of Prof. E.J. Corey at Harvard University, Cambridge, USA as postdoctoral fellow. After that he continued his career, working in Discovery Research in Medicinal Chemistry at Bayer, Wuppertal and at Aventis, Frankfurt. In 2009, he joined Grünenthal in Aachen, Germany where he currently acts as Vice President and Global Head of Drug Discovery.
Volume 1:
PRINCIPLES OF TUMOR TARGETING
Limits of Conventional Cancer Chemotherapy
Pathophysiological and Vascular Characteristics of Tumors in Relation to Drug Delivery
Enhanced Permeability and Retention Effect in Relation to Tumor Targeting
Pharmacokinetics of Immunoglobulin G and Serum Albumin: Impact of the Neonatal Fc Receptor on Drug Design
Development of Cancer-Targeting Ligands and Ligand-Drug Conjugates
Antibody-Directed Enzyme Prodrug Therapy (ADEPT) - Basic Principles and its Practice So Far
TUMOR IMAGING
Imaging Techniques in Drug Development and Clinical Practice
Magnetic Nanoparticles in Magnetic Resonance Imaging and Drug Delivery
Preclinical and Clinical Tumor Imaging with SPECT/CT and PET/CT
Volume 2:
MACROMOLECULAR DRUG DELIVERY SYSTEMS
Antibody-Based Systems
Empowered Antibodies for Cancer Therapy
Mapping Accessible Vascular Targeting to Penetrate Organs and Solid Tumors
Considerations of Linker Technologies
Antibody-Maytansinoid Conjugates: From the Bench to the Clinic
Calicheamicin Antibody-Drug Conjugates and Beyond
Antibodies for the Delivery of Radionuclides
Bispecific Antibodies and Immune Therapy Targeting
POLYMER-BASED SYSTEMS
Design of Polymer-Drug Conjugates
Dendritic Polymers in Oncology: Facts, Features, and Applications
Site-Specific Prodrug Activation and the Concept of Self-Immolation
Ligand-Assisted Vascular Targeting of Polymer Therapeutics
Drug Conjugates with Poly(Ethylene)Glycole
Thermo-Responsive Polymers
Polysaccharide-Based Drug Conjugates for Tumor Targeting
Serum Proteins as Drug Carriers of Anticancer Agents
Future Trends, Challenges, and Opportunities with Polymer-Based Combination Therapy in Cancer
Clinical Experience with Drug-Polymer Conjugates
NANO- AND MICROPARTICULATE DRUG DELIVERY SYSTEMS - LIPID-BASED SYSTEMS
Overview on Nanocarriers as Delivery Systems
Development of PEGylated Liposomes
Immunoliposomes
Responsive Liposomes (for Solid Tumor Therapy)
Nanoscale Delivery Systems for Combination Chemotherapy
NANO- AND MICROPARTICULATE DRUG DELIVERY SYSTEMS - POLYMER-BASED SYSTEMS
Micellar Strcutures as Drug Delivery Systems
Tailor-Made Hydrogels for Tumor Delivery
pH-Triggered Micelles for Tumor Delivery
Albumin-Drug Nanoparticles
Carbon Nanotubes
Volume 3:
LIGAND-BASED DRUG DELIVERY SYSTEMS
Cell-Penetrating Peptides in Cancer Targeting
Targeting to Peptide Receptors
Aptamer Conjugates: Emerging Delivery Platforms for Targeted Cancer Therapy
Design and Synthesis of Drug Conjugates of Vitamins and Growth Factors
Drug Conjugates with Polyunsaturated Fatty Acids
SPECIAL TOPICS
RNA Drug Delivery Approaches
Local Gene Delivery for Therapy of Solid Tumors
Viral Vectors for RNA Interference Applications in Cancer Research and Therapy
Design of Targeted Protein Toxins
Drug Targeting to the Central Nervous System
Liver Tumor Targeting
Photodynamic Therapy: Photosensitizers Targeting and Delivery
Tumor-Targeting Strategies with Anticancer Platinum Complexes
Erscheint lt. Verlag | 23.5.2013 |
---|---|
Sprache | englisch |
Themenwelt | Medizin / Pharmazie ► Medizinische Fachgebiete ► Onkologie |
Naturwissenschaften ► Chemie | |
Schlagworte | Arzneimittelentwicklung • Biotechnologie • Biotechnologie i. d. Biowissenschaften • Biotechnology • Biowissenschaften • Chemie • Chemistry • Drug Formulation & Delivery • Krebs (Medizin) • Life Sciences • Medical oncology • Medical Science • Medizin • medizinische Onkologie • Onkologie • Wirkstoffformulierung, Wirkstofftransport • Wirkstoffforschung |
ISBN-10 | 3-527-64776-7 / 3527647767 |
ISBN-13 | 978-3-527-64776-7 / 9783527647767 |
Haben Sie eine Frage zum Produkt? |
![PDF](/img/icon_pdf_big.jpg)
Größe: 34,8 MB
Kopierschutz: Adobe-DRM
Adobe-DRM ist ein Kopierschutz, der das eBook vor Mißbrauch schützen soll. Dabei wird das eBook bereits beim Download auf Ihre persönliche Adobe-ID autorisiert. Lesen können Sie das eBook dann nur auf den Geräten, welche ebenfalls auf Ihre Adobe-ID registriert sind.
Details zum Adobe-DRM
Dateiformat: PDF (Portable Document Format)
Mit einem festen Seitenlayout eignet sich die PDF besonders für Fachbücher mit Spalten, Tabellen und Abbildungen. Eine PDF kann auf fast allen Geräten angezeigt werden, ist aber für kleine Displays (Smartphone, eReader) nur eingeschränkt geeignet.
Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen eine
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen eine
Geräteliste und zusätzliche Hinweise
Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.
aus dem Bereich